TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15073684

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 376

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 376
Study: 11309551

Group type: EXPERIMENTAL
Intervention: 20 mg of furosemide plus 250 mg of probenecid
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 20 mg of furosemide plus 1000 mg of probenecid
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo plus 20 mg of furosemide
Number of subjects: 100
Study: 9495430

Group type: EXPERIMENTAL
Intervention: Stress hormone cocktail (epinephrine, cortisol, glucagon, angiotensin II, and vasopressin) administered intravenously for 24 hours
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 17
Study: 8039523

Group type: EXPERIMENTAL
Intervention: Aerobic exercise plus dietary restriction (45-60 min/day at 50%-60% VO2max, 3-4 days/week, energy deficit of -1.05 to -1.14 MJ/day)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Aerobic exercise plus dietary restriction
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 32
Study: 2666238

Group type: EXPERIMENTAL
Intervention: Nifuroxazide 400 mg twice daily for 5 days
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Nifuroxazide
Number of subjects: 88
Study: 1103550

Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Diphenylhydantoin (DPH)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Mean serum levels
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Overall effectiveness
Number of subjects: 20
Study: 29665619

Group type: EXPERIMENTAL
Intervention: Pomegranate Extract (PE) - D2 (656 mg phenolics)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Pomegranate Extract (PE) - D2
Number of subjects: 49
Study: 28376767

Group type: EXPERIMENTAL
Intervention: 20,000 IU vitamin D3 weekly
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 26132895

Group type: EXPERIMENTAL
Intervention: 6.4% sucrose solution (SUC)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Noncaloric sweetened placebo (PLA)
Number of subjects: 14
Study: 21599832

Group type: EXPERIMENTAL
Intervention: High insertion torque implants (MIT > 70 Ncm, mean = 110.6 Ncm, range: 70.8‐176 Ncm)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Low insertion torque implants (control group, MIT between 30 and 50 Ncm, mean = 37.1 Ncm)
Number of subjects: 48
Study: 21436223

Group type: EXPERIMENTAL
Intervention: Sublingual cannabis extract (maximum of 10.8 mg tetrahydrocannabinol and 10 mg cannabidiol)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 18472662

Group type: EXPERIMENTAL
Intervention: Outpatient treatment episode
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Additional treatment after initial outpatient episode
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Outpatient treatment only
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Various combinations of outpatient, intensive outpatient, and residential treatment
Number of subjects: 176
Study: 17130515

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ovarian ablation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemotherapy-induced amenorrhea
Number of subjects: 0
Study: 14581111

Group type: EXPERIMENTAL
Intervention: Capsicum plaster
Number of subjects: 320

Group type: COMPARATOR
Intervention: Placebo plaster
Number of subjects: 320
Study: 10897061

Group type: EXPERIMENTAL
Intervention: IFN plus NAC (3MU IFN-alpha thrice weekly plus NAC 1800 mg daily)
Number of subjects: 147

Group type: COMPARATOR
Intervention: IFN alone
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: IFN plus NAC
Number of subjects: 147
Study: 8819554

Group type: EXPERIMENTAL
Intervention: Sucrose 24% (S24, n = 8)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Sucrose 12% (S12, n = 8)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Spring water (W, n = 12)
Number of subjects: 28
Study: 1420739

Group type: EXPERIMENTAL
Intervention: 20 mg omeprazole o.m.
Number of subjects: 241

Group type: COMPARATOR
Intervention: 40 mg famotidine nocte
Number of subjects: 241
Study: 3917660

Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Nitroprusside
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Volume loading with nitroglycerin
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Volume loading with nitroprusside
Number of subjects: 33
Study: 31728054

Group type: EXPERIMENTAL
Intervention: Delayed Intensification (DI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 24-hour intravenous methotrexate (IV MTX) infusion (1 g/m2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 4-hour intravenous methotrexate (IV MTX) infusion (2 g/m2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Minimal Residual Disease (MRD) <0.01%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Minimal Residual Disease (MRD) ≥0.01%
Number of subjects: 0
Study: 29529157

Group type: EXPERIMENTAL
Intervention: Behavioral lifestyle intervention with partial meal replacement
Number of subjects: 257

Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 257
Study: 26282334

Group type: EXPERIMENTAL
Intervention: Watching one's own back (visual feedback)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Watching a neutral object (book)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Watching a video of another person of the same sex
Number of subjects: 19

Group type: COMPARATOR
Intervention: Watching a picture of the own back
Number of subjects: 19

Group type: COMPARATOR
Intervention: Keeping one's eyes closed
Number of subjects: 19
Study: 24877778

Group type: EXPERIMENTAL
Intervention: Medienhelden program (ten-week curriculum)
Number of subjects: 570

Group type: EXPERIMENTAL
Intervention: Medienhelden program (single project day)
Number of subjects: 570

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 570
Study: 22290342

Group type: EXPERIMENTAL
Intervention: Comprehensive self-management (CSM) intervention
Number of subjects: 175

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 175
Study: 20238247

Group type: EXPERIMENTAL
Intervention: Modified-release esomeprazole 60 mg od
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Modified-release esomeprazole 80 mg od
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Modified-release esomeprazole 40 mg od
Number of subjects: 55

Group type: COMPARATOR
Intervention: Conventional formulation esomeprazole 20 mg bid
Number of subjects: 55

Group type: COMPARATOR
Intervention: Conventional formulation esomeprazole 40 mg bid
Number of subjects: 55
Study: 17662431

Group type: EXPERIMENTAL
Intervention: Verisyse pIOL
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Artiflex pIOL
Number of subjects: 11

Group type: COMPARATOR
Intervention: Both pIOLs
Number of subjects: 11
Study: 15464320

Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 70

Group type: COMPARATOR
Intervention: Ticlopidine
Number of subjects: 70
Study: 11246179

Group type: EXPERIMENTAL
Intervention: Structured preoperative instructions
Number of subjects: 0
Study: 9589225

Group type: EXPERIMENTAL
Intervention: Reduced-energy formula diet (1,100 ± 250 kcal/day)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Weight loss (6.3 ± 0.4 kg)
Number of subjects: 20
Study: 7992938

Group type: EXPERIMENTAL
Intervention: Fraxiparine (0.3 mL, 3,075 anti Xa IU per day, one daily subcutaneous injection)
Number of subjects: 480

Group type: COMPARATOR
Intervention: Calciparine (0.2 mL t.i.d., 15,000 IU per day, one subcutaneous injection)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 480
Study: 2514323

Group type: EXPERIMENTAL
Intervention: Ro 15‐1788 (Benzodiazepine antagonist)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Physostigmine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 30852528

Group type: EXPERIMENTAL
Intervention: HeART of Stroke (HoS) intervention (ten 2-hour sessions over 14 weeks) plus usual care
Number of subjects: 56

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 56
Study: 29170073

Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl
Number of subjects: 212

Group type: COMPARATOR
Intervention: No intravenous fentanyl (control)
Number of subjects: 212
Study: 27000445

Group type: EXPERIMENTAL
Intervention: Pazopanib
Number of subjects: 1110

Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 1110
Study: 25255113

Group type: EXPERIMENTAL
Intervention: Inverted T-shaped reduction
Number of subjects: 255

Group type: COMPARATOR
Intervention: Vertical scar reduction
Number of subjects: 255

Group type: COMPARATOR
Intervention: Vertical scar reduction (for reductions less than 500 g)
Number of subjects: 255
Study: 22221076

Group type: EXPERIMENTAL
Intervention: telcagepant (280-mg tablet/300-mg capsule)
Number of subjects: 165

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 165
Study: 20669013

Group type: EXPERIMENTAL
Intervention: Erythromycin (500 mg three times daily for 3 days)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Erythromycin (500 mg three times daily for 3 days) in CYP2C19 HEMs and PMs
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Erythromycin (500 mg three times daily for 3 days) in CYP2C19 EMs
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: CYP2C19 genotypes (EMs, HEMs, PMs)
Number of subjects: 18
Study: 17573359

Group type: EXPERIMENTAL
Intervention: AutoCapture devices with steroid‐eluting epicardial leads
Number of subjects: 56
Study: 16288378

Group type: EXPERIMENTAL
Intervention: vCP205 vaccine formulation (10(6.08) TCID(50))
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: vCP205 vaccine formulation (10(6.33) TCID(50))
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: vCP205 vaccine (both formulations)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11843746

Group type: EXPERIMENTAL
Intervention: Oxygen (40%) by facemask
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Air by facemask
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Oxygen at 2 l x min(‐1) by nasal cannulae
Number of subjects: 69

Group type: COMPARATOR
Intervention: Facemask
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Nasal cannulae
Number of subjects: 69
Study: 10078402

Group type: EXPERIMENTAL
Intervention: Granisetron 20 micrograms.kg‐1
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Granisetron 40 micrograms.kg‐1
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 7675371

Group type: EXPERIMENTAL
Intervention: Interceed (TC7) Absorbable Adhesion Barrier
Number of subjects: 32

Group type: COMPARATOR
Intervention: Surgery alone (Control)
Number of subjects: 32
Study: 2116747

Group type: EXPERIMENTAL
Intervention: Refeeding (16 days, 1,000 kcal above usual intake)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham feeding (16 days, 100 kcal above usual intake)
Number of subjects: 10
Study: 6992131

Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (Normal subjects)
Number of subjects: 0
Study: 31182134

Group type: EXPERIMENTAL
Intervention: STOP intervention (training for pharmacy staff and environmental prompts)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: STOP intervention
Number of subjects: 60
Study: 28438906

Group type: EXPERIMENTAL
Intervention: Artificial Neural Network (ANN) model for diagnosis of ACI
Number of subjects: 260
Study: 25491659

Group type: EXPERIMENTAL
Intervention: Physician (MD) introduction
Number of subjects: 137

Group type: COMPARATOR
Intervention: Non-physician (non-MD) introduction
Number of subjects: 137
Study: 24662288

Group type: EXPERIMENTAL
Intervention: FX CorDiax 60
Number of subjects: 30

Group type: COMPARATOR
Intervention: FX 60
Number of subjects: 30
Study: 22365555

Group type: EXPERIMENTAL
Intervention: Computerized cognitive training (80 hours)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Computerized cognitive training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Computer games control condition
Number of subjects: 0
Study: 19496103

Group type: EXPERIMENTAL
Intervention: Fluoxetine 40 mg/day plus celecoxib 400 mg/day (200 mg bid)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Fluoxetine 40 mg/day plus placebo
Number of subjects: 40
Study: 17992915

Group type: EXPERIMENTAL
Intervention: Colgate Pokemon (Colgate‐Palmolive, Thailand)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Perioe Children's Toothpaste (LG, Korea)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Vicco (Vicco Laboratories, India)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control Group (not explicitly mentioned)
Number of subjects: 21
Study: 15691622

Group type: EXPERIMENTAL
Intervention: Transcendental Meditation (TM)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Progressive Muscle Relaxation (PMR)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Health Education (HE)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Transcendental Meditation (TM) for women
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Transcendental Meditation (TM) for men
Number of subjects: 150
Study: 11915064

Group type: EXPERIMENTAL
Intervention: Continuous infusion (10 mL/h)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Patient-controlled analgesia (5 mL/h basal rate with 5 mL bolus every 60 minutes)
Number of subjects: 50
Study: 9620430

Group type: EXPERIMENTAL
Intervention: Eradication therapy
Number of subjects: 15

Group type: COMPARATOR
Intervention: Follow-up only
Number of subjects: 15
Study: 7890496

Group type: EXPERIMENTAL
Intervention: Vistech-Teller Acuity Cards (TAC) for binocular and monocular grating visual acuity (VA)
Number of subjects: 646

Group type: EXPERIMENTAL
Intervention: Vistech-Teller Acuity Cards (TAC)
Number of subjects: 646
Study: 1978475

Group type: EXPERIMENTAL
Intervention: Remoxipride CR (385 mg daily)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Haloperidol (17 mg daily)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Remoxipride CR
Number of subjects: 114
Study: 7398099

Group type: EXPERIMENTAL
Intervention: 1.0 micrograms 1 alpha(OH)D3
Number of subjects: 20

Group type: COMPARATOR
Intervention: 0.5 micrograms 1 alpha(OH)D3
Number of subjects: 20
Study: 31838259

Group type: EXPERIMENTAL
Intervention: Education and household training on best-burn practices (Tx1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indoor air filtration unit (Tx2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control arm (Tx3)
Number of subjects: 0
Study: 31800542

Group type: EXPERIMENTAL
Intervention: Crofelemer (125 mg)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study: 28131677

Group type: EXPERIMENTAL
Intervention: Double-layer amniotic membrane transplantation
Number of subjects: 99

Group type: COMPARATOR
Intervention: Routine antibacterial therapy
Number of subjects: 99
Study: 25890359

Group type: EXPERIMENTAL
Intervention: Particle-filtered air exposure
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham-filtered air exposure
Number of subjects: 60
Study: 23806933

Group type: EXPERIMENTAL
Intervention: Fibrin sealant plus self-adhesive fabric dressing
Number of subjects: 50

Group type: COMPARATOR
Intervention: Self-adhesive fabric dressing only (control)
Number of subjects: 50
Study: 17699383

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Higher log IL-6
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Higher APACHE II score
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Dependence on activity of daily living scale
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Baseline platelet count
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Baseline respiratory Sepsis Organ Failure Assessment score
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 547
Study: 15219887

Group type: COMPARATOR
Intervention: Clomiphene citrate (CC) 100 mg daily for 5 days
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC) 100 mg daily for 5 days + phytoestrogens (PE) 1500 mg daily for 10 days
Number of subjects: 134
Study: 10798461

Group type: EXPERIMENTAL
Intervention: Combined behavioral and drug therapy (biofeedback-assisted behavioral training followed by oxybutynin chloride titrated from 2.5 mg to 15 mg daily)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Drug therapy (oxybutynin chloride)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Behavioral treatment
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Combined drug and behavioral treatment
Number of subjects: 197
Study: 8831328

Group type: EXPERIMENTAL
Intervention: Mivacurium 250 micrograms/kg
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Rocuronium 600 micrograms/kg
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Vecuronium 100 micrograms/kg
Number of subjects: 70

Group type: COMPARATOR
Intervention: Mivacurium 250 micrograms/kg after rocuronium
Number of subjects: 70

Group type: COMPARATOR
Intervention: Mivacurium 250 micrograms/kg after vecuronium
Number of subjects: 70

Group type: COMPARATOR
Intervention: Vecuronium after mivacurium
Number of subjects: 70

Group type: COMPARATOR
Intervention: Rocuronium after mivacurium
Number of subjects: 70
Study: 1305819

Group type: EXPERIMENTAL
Intervention: Single dose of 6 puffs (1500 micrograms) of terbutaline
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 3 doses of 2 puffs (500 micrograms) of terbutaline at 15-minute intervals
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 3 doses of 2 puffs (500 micrograms) of terbutaline at 5-minute intervals
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study: 3888153

Group type: EXPERIMENTAL
Intervention: Ticlopidine
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 31939036

Group type: EXPERIMENTAL
Intervention: Intradermal botulinum toxin A (50 units)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Fractional microneedle radiofrequency (FMR)
Number of subjects: 20
Study: 31391076

Group type: EXPERIMENTAL
Intervention: Specific rehabilitation programme combining relearning of motor control and self-management strategies
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Specific rehabilitation programme
Number of subjects: 50
Study: 27995626

Group type: EXPERIMENTAL
Intervention: PVC tracheal tube
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Reinforced tracheal tube
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: BlockBuster tracheal tube
Number of subjects: 177
Study: 25578925

Group type: EXPERIMENTAL
Intervention: CM+CHW
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: CM
Number of subjects: 207

Group type: COMPARATOR
Intervention: UC
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: CM+CHW (men)
Number of subjects: 207
Study: 23701209

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control session
Number of subjects: 19
Study: 21820521

Group type: EXPERIMENTAL
Intervention: IA-BioHA
Number of subjects: 433

Group type: COMPARATOR
Intervention: IA-SA
Number of subjects: 433
Study: 19138360

Group type: EXPERIMENTAL
Intervention: Alfuzosin 10 mg once a day
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg on alternative days
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Combination of alfuzosin and tadalafil
Number of subjects: 66
Study: 16960448

Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg/day)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Pravastatin (80 mg/day)
Number of subjects: 23
Study: 15063917

Group type: EXPERIMENTAL
Intervention: Disulfiram
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 11190581

Group type: EXPERIMENTAL
Intervention: Quinapril 20 mg/day (n = 12)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Non-quinapril group (n = 12)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Quinapril group
Number of subjects: 24

Group type: COMPARATOR
Intervention: Non-quinapril group
Number of subjects: 24
Study: 9332997

Group type: EXPERIMENTAL
Intervention: Dopamine infusion at a rate of 1 to 5 microg/kg per minute
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (sterile water)
Number of subjects: 40
Study: 8404293

Group type: EXPERIMENTAL
Intervention: Ampicillin/sulbactam
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Cefoxitin
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Piperacillin/metronidazole
Number of subjects: 422

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 422
Study: 2877643

Group type: EXPERIMENTAL
Intervention: Beta-blockade with betaxolol (oral, cardioselective) during clinical beta-blockade (heart rate 50 to 60 beats per minute, <20% increase in heart rate over baseline during stage I treadmill exercise, Bruce protocol)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 31807900

Group type: EXPERIMENTAL
Intervention: NMES at short muscle length (50°)
Number of subjects: 10

Group type: COMPARATOR
Intervention: NMES at long muscle length (100°)
Number of subjects: 10
Study: 29763434

Group type: EXPERIMENTAL
Intervention: 600 mg ibuprofen 3 times a day for 3 days
Number of subjects: 383

Group type: COMPARATOR
Intervention: 200 mg pivmecillinam 3 times a day for 3 days
Number of subjects: 383
Study: 27150261

Group type: EXPERIMENTAL
Intervention: ABT-981 (0.3, 1, 3, or 10 mg/kg intravenously; 0.3, 1, 3 mg/kg subcutaneously)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: ABT-981 (3 mg/kg subcutaneously every 4 weeks)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: ABT-981 (subcutaneous doses every 2 weeks)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: ABT-981
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 24844765

Group type: EXPERIMENTAL
Intervention: LEOPIN ROYAL® (LER)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Kampo (mainly kamishoyosan)
Number of subjects: 49